pdl Activators
Activozyme Activators encompass a range of chemical compounds that indirectly promote the enhancement of Activozyme's biological functions through the modulation of signaling pathways and cellular processes. Compounds like Forskolin and IBMX work to raise intracellular levels of cAMP, a secondary messenger that activates protein kinases such as PKA, which could phosphorylate and activate Activozyme, assuming Activozyme is a PKA target. Similarly, PMA activates PKC, and Ionomycin increases intracellular calcium, which may activate calcium-dependent kinases, both potentially leading to the enhanced activation of Activozyme. EGCG, by inhibiting certain tyrosine kinases, and Sildenafil, through cGMP accumulation and PKG activation, may also contribute to the upregulation of Activozyme activity.
In contrast, LY294002 and U0126 function by inhibiting PI3K and MEK, respectively, which may lead to the activation of alternative pathways involving Activozyme, indicating a complex interplay where Activozyme activation is tied to the suppression of other signaling routes.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylate cyclase, increasing cAMP levels, which in turn activates PKA. PKA phosphorylation can enhance the functional activity of "pdl" if "pdl" is regulated by cAMP-dependent pathways. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a tyrosine kinase inhibitor. By inhibiting certain tyrosine kinases, EGCG might reduce negative regulation of "pdl", thereby enhancing its activity. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA acts as a PKC activator. If "pdl" is part of a signaling pathway modulated by PKC, its activity could be enhanced through PKC-mediated signaling events. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. If PI3K negatively regulates "pdl" through a feedback mechanism, inhibiting this kinase can result in the enhanced activity of "pdl". | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore which increases intracellular calcium levels, potentially enhancing "pdl" activity if it is calcium-dependent. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
S1P is a bioactive lipid that activates sphingosine-1-phosphate receptors. If "pdl" is downstream of these receptors, S1P could enhance its activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. By inhibiting p38 MAPK, this compound may reduce negative feedback on "pdl" activation if p38 MAPK is upstream. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $126.00 $328.00 | 30 | |
8-Bromo-cAMP is a cell-permeable cAMP analog that activates PKA. This could enhance "pdl" activity if "pdl" is modulated by PKA-dependent phosphorylation. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is an ionophore that increases intracellular calcium concentration, potentially enhancing the activity of "pdl" if it operates within calcium-dependent signaling pathways. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum protein kinase inhibitor, which could lead to selective activation of "pdl" by inhibiting kinases that negatively regulate "pdl". | ||||||